{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:06:21Z","timestamp":1792415181567,"version":"4.4.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative colitis. Results are presented from the open-label extension study through W104.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical, symptomatic, quality-of-life, and adverse event outcomes are reported for mirikizumab induction responders and extended induction responders, including biologic-failed patients, who entered LUCENT-3, with data shown for W52 maintenance responders or remitters. Discontinuations or missing data were handled by nonresponder imputation (NRI), modified NRI (mNRI), and observed case (OC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among W52 mirikizumab responders, clinical response at W104 was 74.5%, 87.2%, and 96.7% and clinical remission was 54.0%, 62.8%, and 70.1% for NRI, mNRI, and OC, respectively. Among W52 mirikizumab remitters, clinical response at W104 was 76.6%, 89.0%, and 98.3% and clinical remission was 65.6%, 76.1%, and 84.2%. Using mNRI, remission rates at W104 for W52 clinical remitters were 74.7% corticosteroid-free, 79.5% endoscopic, 63.9% histologic-endoscopic mucosal remission, 85.9% symptomatic, 59.8% bowel urgency, 80.5% Inflammatory Bowel Disease Questionnaire (using NRI), 71.2% histologic-endoscopic mucosal improvement, and 77.5% bowel urgency improvement. Previous biologic-failed vs not-biologic-failed patient data were generally similar. Extended induction mNRI clinical response was 81.9%. Serious adverse events were reported in 5.2% of patients; 2.8% discontinued treatment due to adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Endoscopic, histologic, symptomatic, and quality-of-life outcomes support the long-term benefit of mirikizumab treatment up to 104 weeks in patients with ulcerative colitis, including biologic-failed patients, with no new safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izae024","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T15:56:08Z","timestamp":1706543768000},"page":"2245-2258","source":"Crossref","is-referenced-by-count":55,"title":["Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study"],"prefix":"10.1093","volume":"30","author":[{"given":"Bruce E","family":"Sands","sequence":"first","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers , Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-8285","authenticated-orcid":false,"given":"David B","family":"Clemow","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Irving","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St. Thomas\u2019 NHS Foundation Trust, King\u2019s College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan T","family":"Johns","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Hunter Gibble","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-0574","authenticated-orcid":false,"given":"Maria T","family":"Abreu","sequence":"additional","affiliation":[{"name":"UHealth Crohn\u2019s and Colitis Center, University of Miami Miller School of Medicine , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lee","sequence":"additional","affiliation":[{"name":"Digestive Health Center, University of Washington Medical Center , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"Severine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, UZ Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A","family":"Siegel","sequence":"additional","affiliation":[{"name":"Dartmouth Hitchcock Medical Center , Lebanon, NH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, INFINY Institute, FHU-CURE, French Institute of Health and Medical Research Nutrition\u2013Genetics and Exposure to Environmental Risks Research Unit, Nancy University Hospital , Nancy ,","place":["France"]},{"name":"Paris IBD Center, Groupe Hospitalier Priv\u00e9 Ambroise Par\u00e9\u2013Hartmann , Neuilly-sur-Seine ,","place":["France"]},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre , Montreal, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Moses","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Milata","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Arora","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Group, Cumming School of Medicine, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Agaplesion Markus Krankenhaus , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"issue":"4","key":"2024121018554420900_CIT0001","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ibd.20301","article-title":"Quality of life of patients with ulcerative colitis: past, present, and future","volume":"14","author":"Irvine","year":"2008","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024121018554420900_CIT0002","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1053\/j.gastro.2019.01.073","article-title":"P024 Patient and healthcare provider views on ulcerative colitis treatment goals and quality of life: results of a global ulcerative colitis narrative survey","volume":"156","author":"Dubinsky","year":"2019","journal-title":"Gastroenterology."},{"issue":"10401","key":"2024121018554420900_CIT0003","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet."},{"key":"2024121018554420900_CIT0004","article-title":"Unmet medical needs in the management of ulcerative colitis: results of an Italian Delphi consensus","volume":"2019:3108025","author":"Daperno","year":"2019","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"2024121018554420900_CIT0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000496739","article-title":"Unmet medical needs in ulcerative colitis: an expert group consensus","volume":"37","author":"Danese","year":"2019","journal-title":"Dig Dis."},{"issue":"7","key":"2024121018554420900_CIT0006","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MEG.0000000000000378","article-title":"Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn\u2019s disease: a systematic review and clinician surveys","volume":"27","author":"Gordon","year":"2015","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"1","key":"2024121018554420900_CIT0007","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"2024121018554420900_CIT0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.med.60.051407.123757","article-title":"IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease","volume":"60","author":"Abraham","year":"2009","journal-title":"Annu Rev Med."},{"issue":"12","key":"2024121018554420900_CIT0009","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut."},{"issue":"26","key":"2024121018554420900_CIT0010","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med."},{"issue":"3","key":"2024121018554420900_CIT0011","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2024121018554420900_CIT0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024121018554420900_CIT0013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","author":"Public Policy Committee, International Society of Pharmacoepidemiology","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"2024121018554420900_CIT0014","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s41687-022-00522-2","article-title":"Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"issue":"158","key":"2024121018554420900_CIT0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc."},{"issue":"8","key":"2024121018554420900_CIT0016","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med."},{"key":"2024121018554420900_CIT0017","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987","edition":"1"},{"issue":"1","key":"2024121018554420900_CIT0018","doi-asserted-by":"crossref","first-page":"109-118.e5","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy\u2019s Law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles\u2013Diaz","year":"2014","journal-title":"Gastroenterology."},{"issue":"1","key":"2024121018554420900_CIT0019","doi-asserted-by":"crossref","first-page":"otac044","DOI":"10.1093\/crocol\/otac044","article-title":"Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission","volume":"5","author":"Dubinsky","year":"2022","journal-title":"Crohns Colitis 360"},{"issue":"3","key":"2024121018554420900_CIT0020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2024121018554420900_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41575-019-0211-1","article-title":"Evolving therapeutic goals in ulcerative colitis: towards disease clearance","volume":"17","author":"Danese","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"5","key":"2024121018554420900_CIT0022","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"7","key":"2024121018554420900_CIT0023","doi-asserted-by":"crossref","first-page":"e00578","DOI":"10.14309\/ctg.0000000000000578","article-title":"Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study","volume":"14","author":"Steere","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"issue":"4","key":"2024121018554420900_CIT0024","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"11-12","key":"2024121018554420900_CIT0025","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/apt.16119","article-title":"Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy","volume":"52","author":"Panaccione","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024121018554420900_CIT0026","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/mi.2012.24","article-title":"The role of neutrophils during intestinal inflammation","volume":"5","author":"Fournier","year":"2012","journal-title":"Mucosal Immunol"},{"issue":"11","key":"2024121018554420900_CIT0027","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/j.cgh.2019.12.011","article-title":"Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis","volume":"18","author":"Pai","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"11","key":"2024121018554420900_CIT0028","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO Position Paper: harmonization of the approach to ulcerative colitis histopathology","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2024121018554420900_CIT0029","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","article-title":"Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programs","volume":"17","author":"Magro","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2024121018554420900_CIT0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","article-title":"Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2024121018554420900_CIT0031","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/PROM.S378759","article-title":"Exploring disease remission and bowel urgency severity among adults with moderate to severe ulcerative colitis: a qualitative study","volume":"13","author":"Dubinsky","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"issue":"3","key":"2024121018554420900_CIT0032","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","article-title":"A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective","volume":"13","author":"Louis","year":"2020","journal-title":"Patient"},{"issue":"12","key":"2024121018554420900_CIT0033","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1007\/s11136-020-02606-2","article-title":"An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score","volume":"29","author":"van Deen","year":"2020","journal-title":"Qual Life Res."},{"issue":"5","key":"2024121018554420900_CIT0034","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"issue":"22","key":"2024121018554420900_CIT0035","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"issue":"Suppl_1","key":"2024121018554420900_CIT0036","doi-asserted-by":"crossref","first-page":"S047","DOI":"10.1093\/ecco-jcc\/jjab073.048","article-title":"DOP09 Mirikizumab-induced transcriptome changes in patient biopsies at week 12 are maintained through week 52 in patients with ulcerative colitis","volume":"15","author":"Johnson","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2024121018554420900_CIT0037","doi-asserted-by":"crossref","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","article-title":"A treat-to-target update in ulcerative colitis: a systematic review","volume":"114","author":"Ungaro","year":"2019","journal-title":"Am J Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae024\/57347201\/izae024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/12\/2245\/60924127\/izae024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/12\/2245\/60924127\/izae024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:52:25Z","timestamp":1733842345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/12\/2245\/7624797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,3,9]]},"published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae024","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,3,9]]}}}